2022
Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients
2019
The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery
Mansour SG, Zhang WR, Moledina D, Coca SG, Jia Y, Thiessen-Philbrook H, McArthur E, Inoue K, Koyner JL, Shlipak MG, Wilson FP, Garg AX, Ishibe S, Parikh CR, Consortium T. The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery. American Journal Of Kidney Diseases 2019, 74: 36-46. PMID: 30955944, PMCID: PMC6591032, DOI: 10.1053/j.ajkd.2019.01.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersCardiac Surgical ProceduresCreatinineEndpoint DeterminationFemaleHumansKidneyMaleMiddle AgedNeovascularization, PhysiologicOutcome Assessment, Health CarePostoperative ComplicationsProspective StudiesReceptors, Vascular Endothelial Growth FactorRisk AssessmentUnited StatesVascular Endothelial Growth Factor AConceptsAcute kidney injuryCardiac surgeryAKI durationKidney injuryProangiogenic markersAngiogenesis markersOutcomes of AKILong-term outcomesPlasma VEGF concentrationsTRIBE-AKI cohortAntiangiogenic markersCause mortalityPreoperative concentrationsHospital dischargeProcess of angiogenesisMarker levelsVEGFR1 levelsPGF concentrationsHigher oddsMortality riskHigh riskLower oddsVEGF concentrationsAngiogenic markersSurgery
2018
Kidney Biopsy–Related Complications in Hospitalized Patients with Acute Kidney Disease
Moledina DG, Luciano RL, Kukova L, Chan L, Saha A, Nadkarni G, Alfano S, Wilson FP, Perazella MA, Parikh CR. Kidney Biopsy–Related Complications in Hospitalized Patients with Acute Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2018, 13: 1633-1640. PMID: 30348813, PMCID: PMC6237071, DOI: 10.2215/cjn.04910418.Peer-Reviewed Original ResearchConceptsAcute kidney diseaseBiopsy-related complicationsLow platelet countHospitalized patientsNonhospitalized patientsKidney biopsyKidney diseasePlatelet countHigher BUNFemale sexRisk factorsLarge-sized hematomaStage 1 AKIRate of complicationsProcedure-related bleedingLarger needle gaugeAbdominal ultrasonographyBiopsy cohortBlood transfusionAngiographic interventionMultivariable analysisPostbiopsy complicationsMultivariable associationsHigh riskTransfusion
2017
Evaluating biomarkers for prognostic enrichment of clinical trials
Kerr KF, Roth J, Zhu K, Thiessen-Philbrook H, Meisner A, Wilson FP, Coca S, Parikh CR. Evaluating biomarkers for prognostic enrichment of clinical trials. Clinical Trials 2017, 14: 629-638. PMID: 28795578, PMCID: PMC5714681, DOI: 10.1177/1740774517723588.Peer-Reviewed Original ResearchConceptsPrognostic enrichmentTrial eligibility criteriaClinical trialsEligibility criteriaTrial resultsClinical trial sample sizesOutcomes of interestTrial sample sizeTrial metricsOnly patientsBACKGROUND/Prognostic biomarkerPrognostic performanceHigh riskClinical settingScreening costsBiomarkersTrialsScreening thresholdCalendar timeTrial costsSample sizePatients
2016
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine 2016, 176: 238-246. PMID: 26752337, PMCID: PMC4772730, DOI: 10.1001/jamainternmed.2015.7193.Peer-Reviewed Original ResearchConceptsIncident chronic kidney diseaseChronic kidney diseaseGlomerular filtration rateProton pump inhibitorsPPI useAtherosclerosis RiskInhibitor useFiltration rateReplication cohortPPI usersKidney diseaseCommunity studyHigh riskIncidence of CKDPropensity score-matched nonusersProton pump inhibitor useAcute interstitial nephritisReceptor antagonist usersReceptor antagonist usePopulation-based cohortNew-user designGeisinger Health SystemAntihypertensive medicationsPPI dosingAntagonist use